CTKB - Cytek Biosciences, Inc.
Price:
--
--
|
CONSENSUS:
Buy
DETAILS
|
PRICE TARGET:
$5.13
DETAILS
HIGH:
$5.50
LOW:
$4.75
MEDIAN:
$5.12
CONSENSUS:
$5.13
UPSIDE:
27.93%
Profitability Ratios
| Ratio | Value |
|---|---|
| GP Margin | 51.8% |
| EBIT Margin | -14.6% |
| EBITDA Margin | -8.6% |
| Operating Margin | -20.0% |
| Pretax Margin | -14.8% |
| Cont. Ops Margin | -33.0% |
| Net Margin | -33.0% |
| Bottom Line Margin | -33.0% |
Liquidity Ratios
| Ratio | Value |
|---|---|
| Current Ratio | 5.04 |
| Quick Ratio | 4.42 |
| Solvency Ratio | -0.455 |
| Cash Ratio | 1.17 |
Valuation Ratios
| Ratio | Value |
|---|---|
| Price/Earnings | |
| PEG Ratio | -0.01 |
| Forward PEG | -0.01 |
| Price/Book | 1.89 |
| Price/Sales | 3.20 |
| Price/FCF | -73.56 |
| Price/Op Cash Flow | -137.67 |
Debt Ratios
| Ratio | Value |
|---|---|
| Debt/Assets | 0.0514 |
| Debt/Equity | 0.0695 |
| Debt/Capital | 0.0650 |
| Long-Term Debt/Capital | 0.0015 |
| Financial Leverage | 1.35 |
Cash Flow Ratios
| Ratio | Value |
|---|---|
| Working Capital Turnover | 0.63 |
| Operating Cash Flow Ratio | -0.060 |
| Operating Cash Flow/Sales | -2.3% |
| Free Cash Flow/Operating Cash Flow | 187.2% |
Coverage Ratios
| Ratio | Value |
|---|---|
| Debt Service Coverage | -7.99 |
| Interest Coverage | -85.1983 |
| Short-Term Operating Cash Flow Coverage | -0.74 |
| Operating Cash Flow Coverage | -0.20 |
| Capital Expenditure Coverage | -1.15 |
| Dividend + Capital Expenditure Coverage | -1.15 |
Dividend Ratios
| Ratio | Value |
|---|---|
| Payout Ratio | 0.0000% |
| Dividend Yield | 0.0000% |
| Dividend Yield % | 0.0000% |
| Dividend Per Share | 0.0000 |
Per Share Ratios
| Ratio | Value |
|---|---|
| Revenue/Share | 1.58 |
| EPS | -0.521 |
| Debt/Share | 0.1896 |
| Cash/Share | 2.05 |
| Book Value/Share | 2.68 |
| Tangible BV/Share | 2.41 |
| Equity/Share | 2.68 |
| Operating Cash Flow/Share | -0.037 |
| Capital Expenditure/Share | 0.032 |
| FCF/Share | -0.069 |
Other Ratios
| Ratio | Value |
|---|---|
| Net Income/Earnings Before Tax | 2.230 |
| Earnings Before Tax/EBIT | 0.739 |
| Price/Fair Value | 1.89 |
| Debt/Market Cap | 0.0106 |
| Effective Tax Rate | -123.0% |
| Enterprise Value Multiple | -33.23 |